What is new in bladder pain syndrome/interstitial cystitis?

Current Opinion in Urology

Volumn 18, Issue 4, 2008, Pages 353-358

  Hanno, Philip ^a   Nordling, Jørgen ^b   Van Ophoven, Arndt ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Bladder hypersensitivity; Bladder pain syndrome; Epidemiology; Interstitial cystitis; Treatment

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BCG VACCINE; BOTULINUM TOXIN; DULOXETINE; HEPARIN; HYALURONIC ACID; HYDROCORTISONE; MUSCARINIC RECEPTOR BLOCKING AGENT; PENTOSAN POLYSULFATE; PLACEBO; RESINEFERATOXIN; TRIAMCINOLONE; VANILLOID RECEPTOR STIMULATION AGENT;

BLADDER BIOPSY; BLADDER IRRITATION; BLADDER SURGERY; CHRONIC PAIN; CYSTALGIA; CYSTECTOMY; CYSTOSCOPY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERBARIC OXYGEN; INTERSTITIAL CYSTITIS; MEDICAL RESEARCH; NAUSEA; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; WOMEN'S HEALTH;

CYSTITIS, INTERSTITIAL; HUMANS; UROLOGY;

EID: 44649122171     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3282fcea88     Document Type: Review

References (36)

1. Warren JW, Meyer WA, Greenberg P, et al. Using the International Continence Society's definition of painful bladder syndrome. Urology 2006; 67:1138-1142.
2. Parsons CL, Stein P, Zupkas P, et al. Defective Tamm-Horsfall protein in patients with interstitial cystitis. J Urol 2007; 178:2665-2670.
3. Ingber MS, Peters KM, Killinger KA, et al. Dilemmas in diagnosing pelvic pain: multiple pelvic surgeries common in women with interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:341-345.
4. Diggs C, Meyer WA, Langenberg P, et al. Assessing urgency in interstitial cystitis/painful bladder syndrome. Urology 2007; 69:210-214. Adds clinical data to the ongoing discussion about urgency in OAB and BPS.
5. Van De Merwe J, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 2008; 53:60-67. Provides a general definition and classification system overcoming previous dilemmas in defining and diagnosing interstitial cystitis.
6. Hanno PM. Re-imagining interstitial cystitis. Urol Clin North Am 2008; 35: 91-99. A comprehensive review of the long-lasting controversies in defining and diagnosing interstitial cystitis.
7. Furuya R, Masumori N, Furuya S, et al. Glomerulation observed during transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is a common finding but no predictor of clinical outcome. Urology 2007; 70:922-926.
8. Ito T, Ueda T, Honma Y, Takei M. Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. Int J Urol 2007; 14:1068-1070.
9. Clemens J, Markossian T, Meenan R, et al. Overlap of voiding symptoms, storage symptoms and pain in men and women. J Urol 2007; 178:1354-1358.
10. Shorter B, Lesser M, Moldwin RM, Kushner L. Effect of comestibles on symptoms of interstitial cystitis. J Urol 2007; 178:145-152.
11. Greenberg P, Tracy JK, Meyer WA, et al. Short interval between symptom onset and medical care as an indication of rapid onset of interstitial cystitis/painful bladder syndrome. BJU Int 2007; 100:599-602.
12. Homma Y. Lower urinary tract symptomatology: its definition and confusion. Int J Urol 2008; 15:35-43. Superb, thoughtful article with clear exposition of current controversies and reasonable ways to solve them.
13. Yamaguchi O, Honda K, Nomiya M, et al. Defining overactive bladder as hypersensitivity. Neurourol Urodyn 2007; 26:904-907. Interesting study that shows most frequency episodes associated with overactive bladder are actually related to hypersensitivity rather than urgency as defined by the International Continence Society.
14. Peters KM, Carrico DJ, Kalinowski SE, et al. Prevalence of pelvic floor dysfunction in patients with interstitial cystitis. Urology 2007; 70: 16-18.
15. Peters KM, Killinger KA, Carrico DJ, et al. Sexual function and sexual distress in women with interstitial cystitis: a case-control study. Urology 2007; 70: 543-547.
16. Ottem DP, Carr LK, Perks AE, et al. Interstitial cystitis and female sexual dysfunction. Urology 2007; 69:608-610.
17. Nickel JC, Tripp D, Teal V, et al. Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J Urol 2007; 177:1832-1836. Sexual function is the primary predictor of mental quality of life in interstitial cystitis patients.
18. Kochakarn W, Lertsithichai P, Pummangura W. Bladder substitution by ileal neobladder for women with interstitial cystitis. Int Braz J Urol 2007; 33:486-492.
19. van Ophoven A, Hertle L. The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. J Urol 2007; 177:552-555.
20. Riedl C, Engelhardt PF, Daha LK, et al. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2007; 21 December [Epub ahead of print].
21. Aghamir SM, Mohseni MG, Arasteh S. Intravesical bacillus Calmette-Guerin for treatment of refractory interstitial cystitis. Urol J 2007; 4:18-23.
22. Mayer R, Propert KJ, Peters KM, et al. A randomized controlled trial of intravesical bacillus Calmette-Guerin for treatment refractory interstitial cystitis. J Urol 2005; 173:1186-1191.
23. Propert KJ, Mayer R, Nickel JC, et al. Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin? J Urol 2007; 178 (3 Pt 1):886-890.
24. Propert K, Mayer R, Nickel C, et al. Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo. J Urol 2008; 179:552-555.
25. Peng CH, Kuo HC. Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. Urol Int 2007; 78:78-81.
26. Takahashi S, Yanase M, Inoue R, et al. Intravesical instillation of resiniferatoxin for the patients with interstitial cystitis. Hinyokika Kiyo 2006; 52:911-913.
27. Payne CK, Mosbaugh PG, Forrest JB, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 2005; 173:1590-1594.
28. Peters KM, Feber KM, Bennett RC. A prospective, single-blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis. BJU Int 2007; 100:835-839. Well designed single-blinded study on two different techniques of neuromodulation for BPS.
29. Steinberg AC, Oyama IA, Whitmore KE. Bilateral S3 stimulator in patients with interstitial cystitis. Urology 2007; 69:441-443.
30. Zabihi N, Mourtzinos A, Maher MG, et al. Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:553-557.
31. Davis EL, El Khodary SR, Talbott EO, et al. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol 2008; 179:177-185.
32. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007; 70:463-468.
33. Ahmad I, Sarath Krishna N, Meddings RN. Sequential hydrodistension and intravesical instillation of hyaluronic acid under general anaesthesia for treatment of refractory interstitial cystitis: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:543-546.
34. Taneja R, Jawade KK. A rational combination of intravesical and systemic agents for the treatment of interstitial cystitis. Scand J Urol Nephrol 2007; 28 June [Epub ahead of print]. This study nicely shows that a reasonable multimodal, step-by-step regime will increase the therapeutic response.
35. Tanaka T, Kawashima H, Makino T, et al. Hyperbaric oxygen therapy for interstitial cystitis resistant to conventional treatments. Int J Urol 2007; 14:563-565.
36. van Ophoven A, Rossbach G, Pajonk F, Hertle L. Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. J Urol 2006; 176:1442-1446.